약물 재배치를 활용한 두경부암 치료
Drug Repositioning for Treatment of Head and Neck Cancers
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Head and neck cancer (HNC) is a complex disease that poses significant therapeutic challeng-es. Traditional treatment options such as surgery, radiation, and chemotherapy have limitedefficacy and often result in significant side effects. In recent years, drug repositioning hasemerged as a promising strategy to identify new therapeutic options for HNC. Drug reposi-tioning involves repurposing existing drugs, already approved for other indications, for thetreatment of HNC. This approach takes advantage of existing knowledge about drug safetyand efficacy, reducing the time and cost needed to develop new drugs. By leveraging theknown safety profiles, pharmacokinetic, and pharmacodynamic properties of these drugs,drug repositioning can accelerate the drug development process and reduce costs. In this re-view, the current status of drug repositioning efforts for HNC and the challenges and opportu-nities associated with this approach are discussed. We also highlight some of the most promis-ing drug candidates that have emerged from recent studies and clinical trials. Overall, drugrepositioning has the potential to significantly improve the treatment landscape for HNC andoffer new hope for patients with this challenging disease.
Abstract
Head and neck cancer (HNC) is a complex disease that poses significant therapeutic challeng-es. Traditional treatment options such as surgery, radiation, and chemotherapy have limitedefficacy and often result in significant side effects. In recent years, drug repositioning hasemerged as a promising strategy to identify new therapeutic options for HNC. Drug reposi-tioning involves repurposing existing drugs, already approved for other indications, for thetreatment of HNC. This approach takes advantage of existing knowledge about drug safetyand efficacy, reducing the time and cost needed to develop new drugs. By leveraging theknown safety profiles, pharmacokinetic, and pharmacodynamic properties of these drugs,drug repositioning can accelerate the drug development process and reduce costs. In this re-view, the current status of drug repositioning efforts for HNC and the challenges and opportu-nities associated with this approach are discussed. We also highlight some of the most promis-ing drug candidates that have emerged from recent studies and clinical trials. Overall, drugrepositioning has the potential to significantly improve the treatment landscape for HNC andoffer new hope for patients with this challenging disease.
참고문헌 (56)
- Pushpakom S, "Drug repurposing: Progress, challenges and recommendations", Nat Rev Drug Discov, 18(1), pp.41~58 (2019)
- Hua Y, "Drug repositioning : Progress and challenges in drug discovery for various diseases", Eur J Med Chem, 234, pp.114239~ (2022)
- Cancer Genome Atlas Network, "Comprehensive genomic characterization of head and neck squamous cell carcinomas", Nature, 517(7536), pp.576~582 (2015)
- Gu Z, "Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy", Sci Transl Med, 14(661), pp.eabo5987~ (2022)
- Siegel RL, "Cancer statistics, 2023", CA Cancer J Clin, 73(1), pp.17~48 (2023)
- Chow LQM, "Head and neck cancer", N Engl J Med, 382(1), pp.60~72 (2020)
- Dudley JT, "Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease", Sci Transl Med, 3(96), pp.96ra76~ (2011)
- Dakshanamurthy S, "Predicting new indications for approved drugs using a proteochemometric method", J Med Chem, 55(15), pp.6832~6848 (2012)
- Wisniewski D, "Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases", Cancer Res, 62(15), pp.4244~4255 (2002)
- Blanke CD, "Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT", J Clin Oncol, 26(4), pp.620~625 (2008)
- Corsello SM, "Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling", Nat Cancer, 1(2), pp.235~248 (2020)
- Thun MJ, "Aspirin use and reduced risk of fatal colon cancer", N Engl J Med, 325(23), pp.1593~1596 (1991)
- Chan AT, "Aspirin and the risk of colorectal cancer in relation to the expression of COX-2", N Engl J Med, 356(21), pp.2131~2142 (2007)
- Liao X, "Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival", N Engl J Med, 367(17), pp.1596~1606 (2012)
- Drew DA, "Aspirin and colorectal cancer : The promise of precision chemoprevention", Nat Rev Cancer, 16(3), pp.173~186 (2016)
- Hsieh CC, "Aspirin disrupts the crosstalk of angiogenic and inflammatory cytokines between 4T1 breast cancer cells and macrophages", Mediators Inflamm, 2018, pp.6380643~ (2018)
- De Matteis R, "Aspirin activates resolution pathways to reprogram T cell and macrophage responses in colitis-associated colorectal cancer", Sci Adv, 8(5), pp.eabl5420~ (2022)
- Ye SY, "The efficacy and safety of celecoxib in addition to standard cancer therapy : A systematic review and meta-analysis of randomized controlled trials", Curr Oncol, 29(9), pp.6137~6153 (2022)
- Li L, "Effect of celecoxib plus standard chemotherapy on cancer prognosis : A systematic review and meta-analysis", Eur J Clin Invest, 53(6), pp.e13973~ (2023)
- Solomon SD, "Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention", N Engl J Med, 352(11), pp.1071~1080 (2005)
- Bertagnolli MM, "Celecoxib for the prevention of sporadic colorectal adenomas", N Engl J Med, 355(9), pp.873~884 (2006)
- Tang J, "β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy", Semin Cancer Biol, 23(6 Pt B), pp.533~542 (2013)
- Barron TI, "Beta blockers and breast cancer mortality : A population-based study", J Clin Oncol, 29(19), pp.2635~2644 (2011)
- Shaashua L, "Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial", Clin Cancer Res, 23(16), pp.4651~4661 (2017)
- Caparica R, "Beta-blockers in early-stage breast cancer : A systematic review and meta-analysis", ESMO Open, 6(2), pp.100066~ (2021)
- Zhong S, "β-blocker use and mortality in cancer patients : Systematic review and metaanalysis of observational studies", Eur J Cancer Prev, 25(5), pp.440~448 (2016)
- Hua Y, "Metformin and cancer hallmarks : Shedding new lights on therapeutic repurposing", J Transl Med, 21(1), pp.403~ (2023)
- Rêgo DF, "Effects of metformin on head and neck cancer : A systematic review", Oral Oncol, 51(5), pp.416~422 (2015)
- Coyle C, "Metformin as an adjuvant treatment for cancer : A systematic review and metaanalysis", Ann Oncol, 27(12), pp.2184~2195 (2016)
- Meireles CG, "Effects of metformin on endometrial cancer : Systematic review and meta-analysis", Gynecol Oncol, 147(1), pp.167~180 (2017)
- Ng CW, "Metformin and colorectal cancer: A systematic review, metaanalysis and meta-regression", Int J Colorectal Dis, 35(8), pp.1501~1512 (2020)
- Tsakiridis T, "Metformin in combination with chemoradiotherapy in locally advanced non–small cell lung cancer : The OCOG-ALMERA randomized clinical trial", JAMA Oncol, 7(9), pp.1333~1341 (2021)
- Goodwin PJ, "Effect of metformin vs placebo on invasive disease–free survival in patients with breast cancer: The MA.32 randomized clinical trial", JAMA, 327(20), pp.1963~1973 (2022)
- Jiang W, "Statins : A repurposed drug to fight cancer", J Exp Clin Cancer Res, 40(1), pp.241~ (2021)
- Raval AD, "Association between statins and clinical outcomes among men with prostate cancer : A systematic review and meta-analysis", Prostate Cancer Prostatic Dis, 19(2), pp.151~162 (2016)
- Manthravadi S, "Impact of statin use on cancer recurrence and mortality in breast cancer : A systematic review and meta-analysis", Int J Cancer, 139(6), pp.1281~1288 (2016)
- Cheung KS, "Statins associate with lower risk of biliary tract cancers : A systematic review and meta-analysis", Cancer Med, 12(1), pp.557~568 (2023)
- Lou D, "Association between statins’exposure with incidence and prognosis of gastric cancer : An updated meta-analysis", Expert Rev Clin Pharmacol, 15(9), pp.1127~1138 (2022)
- Lim SH, "randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI", FOLFIRI plus simvastatin for patients with metastatic colorectal cancer, 2015, pp.113(10), 1421~1426
- Seckl MJ, "Multicenter, phase III, randomized, doubleblind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR)", J Clin Oncol, 35(14), pp.1506~1514 (2017)
- Jouve JL, "Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma", J Hepatol, 71(3), pp.516~522 (2019)
- Jeong IG, "Adjuvant low-dose statin use after radical prostatectomy : The PRO-STAT randomized clinical trial", Clin Cancer Res, 27(18), pp.5004~5011 (2021)
- Jameson MB, "SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: An AGITG clinical trial", BMC Cancer, 19(1), pp.1229~ (2019)
- Hamilton RJ, "The association between statin use and outcomes in patients initiating androgen deprivation therapy", Eur Urol, 79(4), pp.446~452 (2021)
- Wilson BE, "Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer : Secondary analysis of COU-AA-301 and COU-AA-302", Eur J Cancer, 170, pp.296~304 (2022)
- Saka-Herrán C, "Head and neck cancer and non-steroidal anti-inflammatory drugs : Systematic review and meta-analysis", Head Neck, 43(5), pp.1664~1682 (2021)
- de la Cour CD, "Non-aspirin NSAIDs and head and neck cancer mortality in a Danish nationwide cohort study", Cancer Epidemiol, 77, pp.102121~ (2022)
- Kim MS, "Pre-diagnostic beta-blocker use and head- and neck cancer risk: A nationwide population-based casecontrol study", Medicine(Baltimore), 98(24), pp.e16047~ (2019)
- Chen HY, "Beta-blocker use is associated with worse relapse-free survival in patients with head and neck cancer", JCO Precis Oncol, 7, pp.e2200490~ (2023)
- Jiao Y, "Survival benefit of metformin as an adjuvant treatment for head and neck cancer : A systematic review and meta-analysis", Front Pharmacol, 13, pp.850750~ (2022)
- Wang Y, "The association between metformin and survival of head and neck cancer : A systematic review and meta-analysis of 7 retrospective cohort studies", Curr Pharm Des, 26(26), pp.3161~3170 (2020)
- Kwon M, "Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival", Oncologist, 20(5), pp.546~553 (2015)
- Bourguillon RO, "Repurposing statin drugs to decrease toxicity and improve survival outcomes in head and neck cancer", OTO Open, 5(4) (2021)
- Kwon M, "Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma", Cancer Lett, 522, pp.198~210 (2021)
- Kansal V, "Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models", J Immunother Cancer, 11(1), pp.e005940~ (2023)
- Chai AWY, "Uncovering drug repurposing candidates for head and neck cancers : Insights from systematic pharmacogenomics data analysis", Sci Rep, 11(1), pp.23933~ (2021)